Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.75 |
| ▸ | MAPT | P10636 | 6/20 | 0.75 |
| ▸ | LMNA | P02545 | 5/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.75 |
| ▸ | HTT | P42858 | 3/20 | 0.75 |
| ▸ | HPGD | P15428 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | MAOB | P27338 | 4/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1784868 | 1.00 | MEN1 (0.75) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL11665349 | 0.87 | MAPT (1.00) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL29892666 | 0.83 | MAOB (0.59) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL27077407 | 0.83 | MAOB (0.59) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL29158527 | 0.77 | MAPT (0.79) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL29158467 | 0.77 | MAPT (0.79) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL8795911 | 0.76 | PTGS2 (0.70) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL5206467 | 0.76 | PTGS2 (0.70) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL22191811 | 0.76 | MEN1 (0.78) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL2843795 | 0.75 | MAPT (0.71) | MEN1KMT2AMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912647-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERICAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-11 | — | — | EP | disclosed |
| US-8017606-B2 | Therapy for bacteria infections other than Mycibacterium infections; antibiotic resistance | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-13 | — | — | US | disclosed |
| US-20110124870-A1 | NOVEL MYCOBACTERIAL INHIBITORS | JANSSEN-CILAG (FR) | 2011-05-26 | — | — | US | disclosed |
| US-7902225-B2 | Mycobacterial inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | disclosed |
| EP-1711181-B1 | QUINOLINE DERIVATIVES AND USE THEREOF AS MYCOBACTERIAL INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-30 | — | — | EP | disclosed |
| US-20080255116-A1 | Therapy for bacteria infections other than Mycibacterium infections; antibiotic resistance | JANSSEN PHARMACEUTICA N.V. | 2008-10-16 | — | — | US | disclosed |
| EP-1912647-A2 | QUINOLINE DERIVATIVES AS ANTIBACTERICAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-23 | — | — | EP | disclosed |
| US-20070093478-A1 | Novel mycobacterial inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | US | disclosed |
| WO-2007014940-A2 | QUINOLINE DERIVATIVES AS ANTIBACTERICAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-08 | — | — | WO | disclosed |
| EP-1711181-A1 | QUINOLINE DERIVATIVES AND USE THEREOF AS MYCOBACTERIAL INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005070430-A1 | QUINOLINE DERIVATIVES AND USE THEREOF AS MYCOBACTERIAL INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124870-A1 | NOVEL MYCOBACTERIAL INHIBITORS | NQO2, NAT1, HRH1 | MEN1 1507/4885KMT2A 3862/4885MAPT 904/4885 |
| US-20070093478-A1 | Novel mycobacterial inhibitors | NQO2, NAT1, HRH1 | MEN1 1792/4885KMT2A 3905/4885MAPT 854/4885 |
| US-20080255116-A1 | Therapy for bacteria infections other than Mycibacterium infections; antibiotic resistance | RER1, HRH4, HRH1 | MEN1 648/4885KMT2A 2701/4885MAPT 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.